entertainment -WSS

entertainment

author：entertainment 2025-10-04 11:35:30 - browse：8969

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： FDA poised to publish guidelines for clinical trial diversity

focus

WSS

Adele warns fans about throwing things at performers onstage

FDA poised to publish guidelines for clinical trial diversity

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

For longer

ASCO eve: Let’s set the table for this year's meeting

Study finds gene variants tied to breast cancer risk in Black women

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

The high cost of giving birth even with insurance

Addressing health care workers' trauma can help fight burnout

How one medical school became remarkably diverse

'Insanity': 4th of July mass shootings across US kill 13, injure more than 80

Virginia high school admissions case could be legal follow

Condition critical? Britain's beloved but battered National Health Service turns 75

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Malaria cases in Florida and Texas: Here’s what you need to know

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

entertainment

'Insanity': 4th of July mass shootings across US kill 13, injure more than 80

Cue Health, Covid

5 shark bites reported on Long Island as officials deploy surveillance drones

The leaders of Italy and Poland say European Union should focus on stopping migration

Citing H5N1 threat, CDC urges peak flu monitoring this summer

The leaders of Italy and Poland say European Union should focus on stopping migration

Wikipedia

focus

hotspot

focus